of newer percutaneous coronary revascularization procedures Long-term outcome of dialysis patients in the United States in dialysis patients. with coronary revascularization procedures.
therapy from January 1978 to June 1995. Patients were identified from the USRDS database of 627,983 patients orbid conditions include atherosclerotic heart disease (ASHD) including myocardial infarction, congestive heart failure (CHF), other cardiac diseases (including der disease, and liver disease.
Abbreviations are: CAB, coronary artery bypass; PTCA, percutaneous transluminal coronary angioplasty.
In-hospital mortality was estimated. Survival time was calculated from the time of revascularization to censor or endpoint. Study endpoints were all-cause death, cardiac death, acute myocardial infarction (AMI), and the comSubject Research Committee of the Hennepin County bined endpoints of AMI or cardiac death. Censoring Medical Center Institutional Review Board. occurred if a patient underwent renal transplantation, had no event at end of study, or was lost to follow-up.
The chi-square test was used to compare differences RESULTS in demographic characteristics by coronary revasculariCoronary revascularization procedures were identified zation procedure. The estimated in-hospital death and event-free survival are summarized in Tables 2 and 3 . The overall inThis study was reviewed and approved by the Human hospital death was 5.4% for PTCA and 12.5% for CAB surgery. For the period of 1990 to 1995, the in-hospital death was 5.5% for PTCA and 12.9% for CAB surgery. Despite the greater in-hospital death, the unadjusted event-free survival was better after CAB surgery for the endpoints of all-cause and cardiac death, AMI, and the combined endpoint of AMI or cardiac death. The overall two-year survival was 56.9% for CAB surgery and 52.9% after PTCA. The two-year cardiac survival was 75.8% for CAB surgery and 72.5% after PTCA. At two years, 8.1% of patients with CAB surgery and 18.8% of PTCA patients had sustained AMI, and 28.7% of patients with CAB surgery and 38.0% of PTCA patients had either AMI or cardiac death. Figures 1-4 display the life-table survival estimates for all-cause death, cardiac death, AMI, and the combined endpoints of AMI or cardiac death, respectively. For each endpoint, survival after CAB surgery versus PTCA was significantly different by the log-rank test.
The effect of independent predictors of all-cause death, cardiac death, AMI, and the combined endpoints of AMI or cardiac death were examined in the Cox proportional hazards model. Table 4 summarizes independent predictors of all-cause death. The most powerful predictors of death were older age (75 years or more, (except ASHD, gallbladder, and liver disease) independently contributed to 15 to 26% increased risk of death in the Cox model. ESRD duration of more than five years (RR ϭ 0.92; 95% CI, 0.86 to 0.99) and female death. Older age and diabetic ESRD were the most gender were associated with a small survival advantage powerful predictors of cardiac death. The impact of co-(RR ϭ 0.94; 95% CI, 0.90 to 0.99). Ethnicity was a more morbidity on cardiac death was similar to its effect on powerful predictor of survival, as nonwhite patients had all-cause death, with PVD independently associated with better outcomes. Compared with whites, black patients 15% increased risk and CHF 31% increased risk of carhad a relative risk of death of 0. The impact of method of coronary revascularization outcomes for CAB surgery versus PTCA. Despite the increased peri-procedure mortality associated with suron survival was also assessed in a logistic regression model employing the same variables used in the Cox gery, the log [Ϫ log (survival)] curves of CAB and PTCA patients (not shown) for all-cause death cross at approximodel, and similar results were obtained. The odds ratio for all-cause death was 0.90 (95% CI, 0.83 to 0.98) for mately nine months and at six months for the cardiac death endpoint. Thus, the short-term survival outcome CAB surgery versus PTCA performed in 1990 to 1995. For cardiac death, the odds ratio was 0.85 (95% CI, 0.78 is actually more favorable with PTCA, but at one year and beyond, the survival outcomes are better with CAB to 0.94) for CAB surgery versus PTCA performed in 1990 to 1995. surgery. Table 6 summarizes independent predictors of AMI. The risk of cardiac death was also analyzed in a Cox model by diabetic status. In nondiabetics, there was a Age and gender were not predictors of AMI occurrence. Black patients had a 12% reduction in AMI risk com-10% lower risk of cardiac death after CAB surgery (RR ϭ 0.897; 95% CI, 0.806 to 0.998) performed in 1990 pared with white patients. The risk of AMI was 21% higher in patients with diabetic renal failure. The only to 1995 compared with PTCA. In diabetic patients, there was a 22% lower risk of cardiac death after CAB surgery comorbid conditions associated with increased AMI risk were prior atherosclerotic heart disease (RR ϭ 1.33; (RR ϭ 0.78; 95% CI, 0.68 to 0.89) compared with PTCA performed in the same period of 1990 to 1995. Figure 5 95% CI, 1.20 to 1.47) and CHF (RR ϭ 1.14; 95% CI, 1.02 to 1.37). The most powerful predictor of AMI in displays the estimated cardiac survival of one group (white, male, age 45 to 64) of diabetic patients after the Cox model was the method of coronary revascularization. Compared with the reference group of PTCA in coronary revascularization.
A stratified Cox model employing the same variables 1990 to 1995, the risk of AMI was 44% lower for patients undergoing CAB surgery in 1978 to 1985, 51% lower in in Tables 4 and 5 , but restricted to patients having coro- Reference group: Age Յ 44; male; white; other ESRD etiology; no co-morbidity; prior ESRD duration Ͻ one year; PTCA 1990-95. Abbreviations are: ASHD, atherosclerotic heart disease; CA, non-skin malagnancy; CAB, coronary artery bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary patients with CAB surgery in 1986 to 1989, and 63% disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD, lower for CAB surgery in 1990 to 1995 (all P Ͻ 0.0001).
end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease. Table 7 summarizes independent predictors of AMI or cardiac death. The most powerful demographic predictors were age of 75 or more (RR ϭ 1.66; 95% CI, 1.44 to 1.91) and diabetic ESRD (RR ϭ 1.29; 95% CI, without prior revascularization. At six months after in-1.19 to 1.39). Similar effects of gender, ethnicity, and tervention, 23% of the CAB group and 60% of the PTCA comorbid conditions were found for independent risk of group had recurrent angina, myocardial infarction, or AMI or cardiac death as were noted for cardiac death cardiac death (P Ͻ 0.0001), with a nonsignificant trend alone. There was a marked reduction in the risk of AMI toward improved survival with surgery (66% two-year or cardiac death following CAB surgery performed in survival with CAB surgery, 51% for PTCA atherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary artery bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease.
The difference in mortality between the two groups was modest; the unadjusted two-year event-free survival for the endpoints of all-cause and cardiac death were 56.9 Ϯ 0.7% and 75.8 Ϯ 0.6% for CAB surgery and 52.9 Ϯ 0.7% 1987 to 1995), the in-hospital death was 8.7% for PTCA and 72.5 Ϯ 0.7% for PTCA, respectively. When eventand 14.5% for CAB surgery (abstract; Chang et al, J Am free survival for AMI is analyzed as a single endpoint Coll Cardiol 29:180A, 1997). Using pooled data available or in combination with cardiac death, there is a greater in 1993, Ko, Kreiger, and Isom reported a 9% operative improvement in long-term survival after CAB surgery mortality for CAB surgery in dialysis patients [21] . The versus PTCA. The survival advantage in the surgical present study provides a more representative picture of group for the all-cause death endpoint occurs approxicoronary revascularization outcomes in dialysis patients, mately one year and beyond after revascularization, sugas it encompasses the experience of dialysis patients in gesting that conventional PTCA may still be appropriate the United States, rather than in a single institution.
for selected short-term palliative indications. In our study the long-term survival of dialysis patients A clearer picture of comparative survival after corowas more favorable after coronary bypass surgery comnary revascularization is provided by the Cox model. pared with coronary angioplasty, despite the higher inAfter adjusting for demographics, comorbidity, and time hospital mortality in the surgical group. Even with a periof revascularization (1990 to 1995), we found that there procedure in-hospital mortality of 5.4% for PTCA and was improved long-term survival of dialysis patients after 12.5% for CAB surgery, the all-cause and cardiac mortal-CAB surgery versus PTCA for all endpoints. The surity were lower with CAB surgery compared with PTCA.
vival improvement after CAB surgery (vs. PTCA) was Despite the early hazard of increased in-hospital death 9% for all-cause death, 15% for cardiac death, 63% for for the surgery patients, the one-year all-cause mortality AMI alone, and 31% for the combined endpoints of AMI and cardiac death in the Cox model. was 29.4% after CAB surgery and 31.1% after PTCA. Reference group: Age Յ 44; male; white; other ESRD etiology; no co-morbidReference group: Age Յ 44; male; white; other ESRD etiology; no co-morbidity; prior ESRD duration Ͻ one year; PTCA 1990-95. Abbreviations are: ASHD, ity; prior ESRD duration Ͻ one year; PTCA 1990-95. Abbreviations are: ASHD, atherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary artery atherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary artery bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD, disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease. coronary angioplasty; PVD, peripheral vascular disease.
Our findings mirror the Bypass Angioplasty Revascuand diabetic nephropathy were independent predictors of all-cause and cardiac death. Our finding of decreased larization Investigation study for the importance of diabetes in survival after coronary revascularization [22] . mortality of black patients after coronary revascularization compared with white patients is consistent with preIn patients with diabetic renal failure, there was a 22% decreased cardiac death risk after CAB surgery comviously published survival data on survival of dialysis patients in the United States [24, 25] . The 19% reduction pared with PTCA performed in 1990 to 1995. In patients without diabetic renal failure, there was only a 10% in all-cause death and 20% reduction in cardiac death risk for black patients compared with white patients is reduction in cardiac death risk after CAB surgery compared with PTCA; this difference was statistically signearly identical to our previously reported survival data after AMI [26] . nificant (P Ͻ 0.05). Although diabetes is a identified risk factor for unfavorable outcomes after coronary revascuThere are several limitations to our study. The USRDS database provides little clinical data. Important prognoslarization procedures, Barsness et al found no significant differential effect of diabetes on outcome between patic factors such as left ventricular ejection fraction, the presence of left main coronary artery disease, and severtients receiving PTCA or CAB surgery for multivessel disease [23] .
ity of coronary artery disease are not identified in the database. Our survival analysis is based on a retrospecOur study confirms the important impact of comorbid conditions and demographics on survival in dialysis pative study design, and biased selection for a particular revascularization procedure could have occurred, which tients undergoing coronary revascularization. Older age
